SK Biopharmaceuticals Co., Ltd.

Total Valuation

SK Biopharmaceuticals Co., Ltd. carries a market capitalization of 6.58T, placing it among publicly traded companies globally. Its enterprise value stands at 7.16T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

SK Biopharmaceuticals Co., Ltd. currently has 78.31M shares outstanding.

Valuation Ratios

SK Biopharmaceuticals Co., Ltd. trades at a trailing price-to-earnings ratio of 21.28. The price-to-sales ratio is 9.39, and the price-to-book ratio stands at -35.40.

Enterprise Valuation

On an enterprise value basis, SK Biopharmaceuticals Co., Ltd. trades at an EV/EBITDA multiple of 26.72 and an EV/FCF ratio of 34.38. The EV/Sales ratio of 9.06 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.72 provides insight into valuation relative to core operating earnings.

Financial Position

SK Biopharmaceuticals Co., Ltd. maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.36, indicating elevated leverage, while an interest coverage ratio of 41.53 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, SK Biopharmaceuticals Co., Ltd. has paid -105.84B in income taxes, reflecting an effective tax rate of 14.86.

Stock Price Statistics

SK Biopharmaceuticals Co., Ltd.'s stock has declined approximately -9.09091% over the past 52 weeks. The 50-day moving average sits at 93,228.00, while the 200-day moving average is 108,742.00.

Income Statement

Over the trailing twelve months, SK Biopharmaceuticals Co., Ltd. generated 790.25B in revenue and converted that into 348.81B in net income, yielding earnings per share of 4,294.22. EBITDA reached 268.03B, while operating income came in at 268.03B.

Balance Sheet

SK Biopharmaceuticals Co., Ltd. holds 310.86B in cash and equivalents against 49.98B in total debt, resulting in a net debt position of -308.99B. Total book value stands at -209.73B, with working capital of 464.73B providing operational flexibility.

Cash Flow

SK Biopharmaceuticals Co., Ltd. produced 166.97B in operating cash flow over the past twelve months. After subtracting -31.98B in capital expenditures, free cash flow totaled 134.99B - equivalent to 1,723.78 per share.

Margins

SK Biopharmaceuticals Co., Ltd. operates with a gross margin of 94.09, reflecting its pricing power and cost economics. The operating margin of 33.92 and net profit margin of 44.14 provide insight into operational efficiency.

Dividends & Yields

Scores

SK Biopharmaceuticals Co., Ltd. posts an Altman Z-Score of 12.96, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.